Orthopedics Today—September 26, 2017
Orthopedics Today reported on a recent study that stated that genetic testing can determine the safest levels of warfarin, a blood thinner, in patients undergoing joint replacement surgery. The study, which was recently published in JAMA and co-authored by HSS rheumatologist Anne R. Bass, MD, found that genetically-guided warfarin doses can reduce the combined risk of major bleeding as well as blood clots.
"This is the first warfarin study done in a large number of orthopedic patients in the modern era and what it shows is that warfarin is as safe as the other anticoagulants and if properly managed, particularly if you use ... genetic information, patients have good outcomes with low rates of blood clots and low rates of major bleeding as well," said Dr. Bass.
This article originally appeared at healio.com.